 | • レポートコード：MRC2303E135 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、253ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に518.4億ドルであった世界の心血管薬市場規模が、2022年に564.4億ドルになり、2027年まで年平均9.11%で成長して875億ドルに達すると予測しています。本レポートでは、心血管薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（抗凝固剤、抗高脂血症薬、降圧剤、抗血小板薬）分析、疾患別（不整脈、冠動脈疾患、高脂血症、高血圧症）分析、投与経路別（経口、非経口）分析、購入形態別（一般用医薬品、処方箋）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、本書には、Abbott Laboratories、Astellas Pharma, Inc.、AstraZeneca、Bayer AG、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Company、Cipla Limited、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Gilead Sciences, Inc.、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Otsuka Holdings Co., Ltd.、Pfizer Inc.、Sanofi S.A.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の心血管薬市場規模：種類別 - 抗凝固剤の市場規模 - 抗高脂血症薬の市場規模 - 降圧剤の市場規模 - 抗血小板薬の市場規模 ・世界の心血管薬市場規模：疾患別 - 不整脈における市場規模 - 冠動脈疾患における市場規模 - 高脂血症における市場規模 - 高血圧症における市場規模 ・世界の心血管薬市場規模：投与経路別 - 経口用心血管薬の市場規模 - 非経口用心血管薬の市場規模 ・世界の心血管薬市場規模：購入形態別 - 一般用医薬品用心血管薬の市場規模 - 処方箋用心血管薬の市場規模 ・世界の心血管薬市場規模：地域別 - 南北アメリカの心血管薬市場規模 アメリカの心血管薬市場規模 カナダの心血管薬市場規模 ブラジルの心血管薬市場規模 ... - アジア太平洋の心血管薬市場規模 日本の心血管薬市場規模 中国の心血管薬市場規模 インドの心血管薬市場規模 韓国の心血管薬市場規模 台湾の心血管薬市場規模 ... -ヨーロッパ/中東/アフリカの心血管薬市場規模 イギリスの心血管薬市場規模 ドイツの心血管薬市場規模 フランスの心血管薬市場規模 ロシアの心血管薬市場規模 ... -その他地域の心血管薬市場規模 ・競争状況 ・企業情報 |
The Global Cardiovascular Drugs Market size was estimated at USD 51.84 billion in 2021 and expected to reach USD 56.44 billion in 2022, and is projected to grow at a CAGR 9.11% to reach USD 87.50 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cardiovascular Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across Anticoagulants, Antihyperlipidemic, Antihypertensive, and Antiplatelet Drugs.
Based on Disease Indication, the market was studied across Arrhythmia, Coronary Artery Disease, Hyperlipidaemia, and Hypertension.
Based on Route of Administration, the market was studied across Oral and Parenteral.
Based on Mode of Purchase, the market was studied across Over-the-Counter Drugs and Prescription-Based Drugs.
Based on End Users, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cardiovascular Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cardiovascular Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cardiovascular Drugs Market, including Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Sanofi S.A., Takeda Pharmaceuticals Company Limited, and Teva Pharmaceuticals.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cardiovascular Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cardiovascular Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cardiovascular Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Cardiovascular Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Cardiovascular Drugs Market?
6. What is the market share of the leading vendors in the Global Cardiovascular Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Cardiovascular Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the global prevalence of cardiac disorders such as strokes and coronary heart failures
5.1.1.2. Increasing R&D investments in gene and peptide therapy for efficient drugs and reimbursement policies
5.1.1.3. Growing consumer expenditures on advanced drugs and therapies
5.1.2. Restraints
5.1.2.1. Stringent regulatory framework and costly patented drugs
5.1.2.2. Selection of advanced medical devices like pacemakers, defibrillators instead of cardiovascular drugs
5.1.3. Opportunities
5.1.3.1. R&D efforts to introduce new effective drugs
5.1.3.2. Favorable reimbursement policies
5.1.4. Challenges
5.1.4.1. Side effects of drugs
5.2. Cumulative Impact of COVID-19
6. Cardiovascular Drugs Market, by Drug Type
6.1. Introduction
6.2. Anticoagulants
6.3. Antihyperlipidemic
6.4. Antihypertensive
6.5. Antiplatelet Drugs
7. Cardiovascular Drugs Market, by Disease Indication
7.1. Introduction
7.2. Arrhythmia
7.3. Coronary Artery Disease
7.4. Hyperlipidaemia
7.5. Hypertension
8. Cardiovascular Drugs Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.3. Parenteral
9. Cardiovascular Drugs Market, by Mode of Purchase
9.1. Introduction
9.2. Over-the-Counter Drugs
9.3. Prescription-Based Drugs
10. Cardiovascular Drugs Market, by End Users
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Americas Cardiovascular Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Cardiovascular Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Cardiovascular Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Astellas Pharma, Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. AstraZeneca
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Bayer AG
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Boehringer Ingelheim GmbH
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Bristol-Myers Squibb Company
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Cipla Limited
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Eli Lilly and Company
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. F. Hoffmann-La Roche Ltd.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Gilead Sciences, Inc.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Johnson & Johnson
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Merck & Co. Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Novartis AG
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Otsuka Holdings Co., Ltd.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Pfizer Inc.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Sanofi S.A.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Takeda Pharmaceuticals Company Limited
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Teva Pharmaceuticals
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing